Loading
A phase 1/2 trial of Ponatinib in acute myeloid leukaemia, chronic myeloid leukaemia, acute lymphoblastic leukaemia and non-Hodgkin lymphoma, run by Incyte Biosciences International Sàrl, now recruiting.
Safety and Efficacy of Ponatinib for Treatment of Pediatric Recurrent or Refractory Leukemias, Lymphomas or Solid Tumors is a phase 1/2 interventional study registered as NCT03934372 by Incyte Biosciences International Sàrl, with 70 participants planned, started 2020-01-29 and due to reach its primary completion in 2028-02-01. Interventions recorded: Ponatinib.
Shares Ponatinib, Chronic myeloid leukaemia (CML), Acute lymphoblastic leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Acute myeloid leukaemia in children, Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Chronic myeloid leukaemia (CML), Acute lymphoblastic leukaemia, Acute myeloid leukaemia and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Acute myeloid leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute lymphoblastic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Acute myeloid leukaemia in children, Acute myeloid leukaemia, Small-molecule kinase inhibitors and the tag pipeline.
Shares Relapsed and refractory acute lymphoblastic leukaemia in children, Acute lymphoblastic leukaemia and the tag pipeline.